

Appendix A: HCPCS Level II Codes for Products Approved by the FDA Under the 505(b)(2) NDA or BLA Pathways and Products “Not Otherwise Classified”

HCPCS Code	Action	Long Descriptor
C9046	Revise	Cocaine hydrochloride nasal solution (goprelto), 1 mg
C9143	Add	Cocaine hydrochloride nasal solution (numbrino), 1 mg
J0131	Revise	Injection, acetaminophen, not otherwise specified, 10 mg
J0134	Add	Injection, acetaminophen (fresenius kabi) not therapeutically equivalent to J0131, 10 mg
J0136	Add	Injection, acetaminophen (b braun) not therapeutically equivalent to J0131, 10 mg
J0173	Add	Injection, epinephrine (belcher) not therapeutically equivalent to J0171, 0.1 mg
J0283	Add	Injection, amiodarone hydrochloride (nexterone), 30 mg
J0610	Revise	Injection, calcium gluconate (fresenius kabi), per 10 ml
J0611	Add	Injection, calcium gluconate (wg critical care), per 10 ml
J0689	Add	Injection, cefazolin sodium (baxter), not therapeutically equivalent to J0690, 500 mg
J0701	Add	Injection, cefepime hydrochloride (baxter), not therapeutically equivalent to maxipime, 500 mg
J0703	Add	Injection, cefepime hydrochloride (b braun), not therapeutically equivalent to maxipime, 500 mg
J0877	Add	Injection, daptomycin (hospira), not therapeutically equivalent to J0878, 1 mg
J0891	Add	Injection, argatroban (accord), not therapeutically equivalent to J0883, 1 mg (for non-esrd use)
J0892	Add	Injection, argatroban (accord), not therapeutically equivalent to J0884, 1 mg (for esrd on dialysis)
J0893	Add	Injection, decitabine (sun pharma) not therapeutically equivalent to J0894, 1 mg
J0898	Add	Injection, argatroban (auromedics), not therapeutically equivalent to J0883, 1 mg (for non-esrd use)
J0899	Add	Injection, argatroban (auromedics), not therapeutically equivalent to J0884, 1 mg (for esrd on dialysis)
J1456	Add	Injection, fosaprepitant (teva), not therapeutically equivalent to J1453, 1 mg
J1574	Add	Injection, ganciclovir sodium (exela) not therapeutically equivalent to J1570, 500 mg
J1611	Add	Injection, glucagon hydrochloride (fresenius kabi), not therapeutically equivalent to J1610, per 1 mg
J1643	Add	Injection, heparin sodium (pfizer), not therapeutically equivalent to J1644, per 1000 units
J2021	Add	Injection, linezolid (hospira) not therapeutically equivalent to J2020, 200 mg
J2184	Add	Injection, meropenem (b. braun) not therapeutically equivalent to J2185, 100 mg

J2247	Add	Injection, micafungin sodium (par pharm) not therapeutically equivalent to J2248, 1 mg
J2251	Add	Injection, midazolam hydrochloride (wg critical care) not therapeutically equivalent to J2250, per 1 mg
J2272	Add	Injection, morphine sulfate (fresenius kabi) not therapeutically equivalent to J2270, up to 10 mg
J2281	Add	Injection, moxifloxacin (fresenius kabi) not therapeutically equivalent to J2280, 100 mg
J2311	Add	Injection, naloxone hydrochloride (zimhi), 1 mg
J2400	Delete	Injection, chloroprocaine hydrochloride, per 30 ml
J2401	Add	Injection, chloroprocaine hydrochloride, per 1 mg
J2402	Add	Injection, chloroprocaine hydrochloride (clorotekal), per 1 mg
J3244	Add	Injection, tigecycline (accord) not therapeutically equivalent to J3243, 1 mg
J3371	Add	Injection, vancomycin hcl (mylan) not therapeutically equivalent to J3370, 500 mg
J3372	Add	Injection, vancomycin hcl (xellia) not therapeutically equivalent to J3370, 500 mg
J9041	Revise	Injection, bortezomib, 0.1 mg
J9044	Delete	Injection, bortezomib, not otherwise specified, 0.1 mg
J9046	Add	Injection, bortezomib, (dr. reddy's), not therapeutically equivalent to J9041, 0.1 mg
J9048	Add	Injection, bortezomib (fresenius kabi), not therapeutically equivalent to J9041, 0.1 mg
J9049	Add	Injection, bortezomib (hospira), not therapeutically equivalent to J9041, 0.1 mg
J1954 ⁴	Add	Injection, leuprolide acetate for depot suspension (lutrate), 7.5 mg
J9314 ⁵	Add	Injection, pemetrexed (teva) not therapeutically equivalent to J9305, 10 mg
J9393	Add	Injection, fulvestrant (teva) not therapeutically equivalent to J9395, 25 mg
J9394	Add	Injection, fulvestrant (fresenius kabi) not therapeutically equivalent to J9395, 25 mg

⁴ Revised November 4, 2022 to add the HCPCS Level II coding changes for MEARIS™ application HCP22070101NT9 that are to become effective January 1, 2023.

⁵ Revised November 4, 2022 to add the HCPCS Level II coding changes for MEARIS™ application HCP220701F5U63 that are to become effective January 1, 2023.